Rheumatoid Arthritis News

Olokizumab combined with methotrexate for the treatment of rheumatoid arthritis maintains its safety and efficacy profile through 106 weeks, according to data published in Annals of the Rheumatic Diseases.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.

Latin American patients with rheumatoid arthritis experience fewer serious adverse events, including major adverse cardiovascular events and malignancy, than patients who are not Latin American, according to a study.

Strictly controlling inflammation can heal bone erosions in rheumatoid arthritis, a process accompanied by changes in the Wnt signaling pathway, according to a presenter at the 2024 Association of Women in Rheumatology conference.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

Although swollen lymph nodes are often common in rheumatology, they are also a “hallmark” of rare, life-threatening diseases, such as IgG4-related disease and Castleman disease, according to data published in Rheumatology.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

Biosimilars have shown to be just as effective as original brand name medications in treating rheumatoid arthritis, and the former may be more cost-effective for patients.